United Therapeutics Corporation
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From United Therapeutics Corporation
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.
Twelve applications with September goal dates include six novel agents but only one breakthrough designation.
PhRMA points to federal court rulings against HHS’s view that companies cannot limit discounts to contract pharmacies. However, there is a split among district courts and while one appellate court has sided with industry two have yet to issue opinions.
Emerging Company Profile: With experienced leadership and new financing, Evommune is developing a topical IRAK4 inhibitor for atopic dermatitis and earlier-stage systemic drugs for various conditions.
- Large Molecule
- Other Names / Subsidiaries
- Lung Biotechnology PBC
- Lung Rx, Inc.
- SteadyMed Ltd.
- SteadyMed Therapeutics, Inc.
- Unither Pharmaceuticals
- Unither Virology
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.